Repatha Safety Data Limited for Pregnancy and Breastfeeding, Manufacturer Launches Pregnancy Registry

The safety profile of Repatha (evolocumab), a widely prescribed cholesterol-lowering medication, remains uncertain for pregnant and breastfeeding individuals due to limited clinical data, according to recent safety reviews. This knowledge gap has prompted manufacturer Amgen to implement a dedicated pregnancy safety monitoring program.

Current Safety Evidence and Clinical Implications

Clinical trials and post-marketing studies have not provided sufficient data to establish the safety profile of Repatha during pregnancy. Healthcare providers face challenges in making evidence-based recommendations for patients who become pregnant while on the medication or who require cholesterol management during pregnancy.

The situation is similar for breastfeeding mothers, as researchers have not determined whether Repatha passes into breast milk or what potential effects it might have on nursing infants. No clinical trials have specifically examined the medication's impact on lactation in either human or animal subjects.

Pregnancy Registry Initiative

In response to these knowledge gaps, Amgen has launched a pregnancy safety study to collect and analyze data from patients who receive Repatha during pregnancy. This registry represents a crucial step toward understanding the medication's safety profile in this population.

"The pregnancy registry will help us gather essential real-world evidence about Repatha's safety during pregnancy," explains a representative from Amgen. Healthcare providers and patients can participate in this important data collection effort by calling 800-772-6436 or visiting the study's dedicated website.

Clinical Recommendations

Healthcare providers are advised to carefully discuss family planning with patients of reproductive age who are receiving or considering Repatha therapy. This includes:

• Evaluating the risks and benefits of continuing treatment during pregnancy
• Discussing appropriate birth control options
• Considering alternative lipid-lowering strategies for pregnant or breastfeeding patients
• Encouraging participation in the pregnancy registry if exposure occurs

The current limitations in safety data highlight the importance of individualized treatment decisions and careful risk-benefit assessment for patients who are pregnant, planning pregnancy, or breastfeeding while managing cholesterol levels.